Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors
Let’s engage.
Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors
May 31, 2025 / 10 Second Read